Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma.

Soriano A, Masanas M, Boloix A, Masiá N, París-Coderch L, Piskareva O, Jiménez C, Henrich KO, Roma J, Westermann F, Stallings RL, Sábado C, de Toledo JS, Santamaria A, Gallego S, Segura MF.

Cell Mol Life Sci. 2019 Jun;76(11):2231-2243. doi: 10.1007/s00018-019-03041-4. Epub 2019 Feb 15.

2.

A physiologically relevant 3D collagen-based scaffold-neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models.

Curtin C, Nolan JC, Conlon R, Deneweth L, Gallagher C, Tan YJ, Cavanagh BL, Asraf AZ, Harvey H, Miller-Delaney S, Shohet J, Bray I, O'Brien FJ, Stallings RL, Piskareva O.

Acta Biomater. 2018 Apr 1;70:84-97. doi: 10.1016/j.actbio.2018.02.004. Epub 2018 Feb 12.

3.

MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE.

Smith S, Fernando T, Wu PW, Seo J, Ní Gabhann J, Piskareva O, McCarthy E, Howard D, O'Connell P, Conway R, Gallagher P, Molloy E, Stallings RL, Kearns G, Forbess L, Ishimori M, Venuturupalli S, Wallace D, Weisman M, Jefferies CA.

J Autoimmun. 2017 May;79:105-111. doi: 10.1016/j.jaut.2017.03.003. Epub 2017 Mar 17.

4.

Hemispherical platinum : silver core : shell nanoparticles for miRNA detection.

Spain E, Adamson K, Elshahawy M, Bray I, Keyes TE, Stallings RL, Forster RJ.

Analyst. 2017 Feb 27;142(5):752-762. doi: 10.1039/c6an02609e.

PMID:
28091676
5.

Assessment of Basic Biological Functions Exerted by miRNAs.

Nolan J, Stallings RL, Piskareva O.

Methods Mol Biol. 2017;1509:11-16.

PMID:
27826913
6.

MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.

Soriano A, París-Coderch L, Jubierre L, Martínez A, Zhou X, Piskareva O, Bray I, Vidal I, Almazán-Moga A, Molist C, Roma J, Bayascas JR, Casanovas O, Stallings RL, Sánchez de Toledo J, Gallego S, Segura MF.

Oncotarget. 2016 Feb 23;7(8):9271-87. doi: 10.18632/oncotarget.7005.

7.

Endoplasmic reticulum stress-mediated upregulation of miR-29a enhances sensitivity to neuronal apoptosis.

Nolan K, Walter F, Tuffy LP, Poeschel S, Gallagher R, Haunsberger S, Bray I, Stallings RL, Concannon CG, Prehn JH.

Eur J Neurosci. 2016 Mar;43(5):640-52. doi: 10.1111/ejn.13160. Epub 2016 Feb 9.

PMID:
26750440
8.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

9.

Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.

Keating SE, Ní Chorcora C, Dring MM, Stallings RL, O'Meara A, Gardiner CM.

Tissue Antigens. 2015 Sep;86(3):172-7. doi: 10.1111/tan.12608. Epub 2015 Jul 22.

PMID:
26202659
10.

The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.

Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, Dowling P, Henry M, O'Sullivan F, Bray I, Stallings RL.

Cancer Lett. 2015 Aug 10;364(2):142-55. doi: 10.1016/j.canlet.2015.05.004. Epub 2015 May 7. Erratum in: Cancer Lett. 2015 Dec 28;369(2):428. Henry, Michael [added].

11.

Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy.

Miller-Delaney SF, Bryan K, Das S, McKiernan RC, Bray IM, Reynolds JP, Gwinn R, Stallings RL, Henshall DC.

Brain. 2015 Mar;138(Pt 3):616-31. doi: 10.1093/brain/awu373. Epub 2014 Dec 30.

12.

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T.

PLoS One. 2014 Dec 11;9(12):e114696. doi: 10.1371/journal.pone.0114696. eCollection 2014.

13.

Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling.

Lee S, Rahnenführer J, Lang M, De Preter K, Mestdagh P, Koster J, Versteeg R, Stallings RL, Varesio L, Asgharzadeh S, Schulte JH, Fielitz K, Schwermer M, Morik K, Schramm A.

PLoS One. 2014 Oct 8;9(10):e108818. doi: 10.1371/journal.pone.0108818. eCollection 2014.

14.

MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.

Planells-Ferrer L, Urresti J, Soriano A, Reix S, Murphy DM, Ferreres JC, Borràs F, Gallego S, Stallings RL, Moubarak RS, Segura MF, Comella JX.

Cell Death Dis. 2014 Sep 4;5:e1401. doi: 10.1038/cddis.2014.356.

15.

Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.

Harvey H, Piskareva O, Creevey L, Alcock LC, Buckley PG, O'Sullivan MJ, Segura MF, Gallego S, Stallings RL, Bray IM.

Int J Cancer. 2015 Apr 1;136(7):1579-88. doi: 10.1002/ijc.29144. Epub 2014 Sep 2.

16.

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.

Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.

Pediatr Blood Cancer. 2014 Oct;61(10):1867-70. doi: 10.1002/pbc.24927. Epub 2014 Jan 4.

PMID:
24391119
17.

Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis.

Bryan K, Terrile M, Bray IM, Domingo-Fernandéz R, Watters KM, Koster J, Versteeg R, Stallings RL.

Nucleic Acids Res. 2014 Feb;42(3):e17. doi: 10.1093/nar/gkt1318. Epub 2013 Dec 18.

18.

Metastasis suppressor microRNA-335 targets the formin family of actin nucleators.

Lynch J, Meehan MH, Crean J, Copeland J, Stallings RL, Bray IM.

PLoS One. 2013 Nov 5;8(11):e78428. doi: 10.1371/journal.pone.0078428. eCollection 2013.

19.

Investigating gene promoter methylation in a mouse model of status epilepticus.

Miller-Delaney SF, Das S, Stallings RL, Henshall DC.

Methods Mol Biol. 2013;1067:87-101. doi: 10.1007/978-1-62703-607-8_7.

PMID:
23975788
20.

Orchestrating osteogenic differentiation of mesenchymal stem cells--identification of placental growth factor as a mechanosensitive gene with a pro-osteogenic role.

McCoy RJ, Widaa A, Watters KM, Wuerstle M, Stallings RL, Duffy GP, O'Brien FJ.

Stem Cells. 2013 Nov;31(11):2420-31. doi: 10.1002/stem.1482.

21.

ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

Wilzén A, Krona C, Sveinbjörnsson B, Kristiansson E, Dalevi D, Øra I, De Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F.

Mol Cancer. 2013 Jul 8;12(1):70. doi: 10.1186/1476-4598-12-70.

22.

Identification of circulating microRNAs in HNF1A-MODY carriers.

Bonner C, Nyhan KC, Bacon S, Kyithar MP, Schmid J, Concannon CG, Bray IM, Stallings RL, Prehn JH, Byrne MM.

Diabetologia. 2013 Aug;56(8):1743-51. doi: 10.1007/s00125-013-2939-4. Epub 2013 May 15.

PMID:
23674172
23.

Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells.

Watters KM, Bryan K, Foley NH, Meehan M, Stallings RL.

BMC Cancer. 2013 Apr 8;13:184. doi: 10.1186/1471-2407-13-184.

24.

MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.

Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL.

Mol Cancer. 2013 Mar 26;12:23. doi: 10.1186/1476-4598-12-23.

25.

Subcortical white matter abnormalities because of previously undescribed de-novo 14q12-q13.1 triplication.

Rea G, Stallings RL, Mullarkey M, McKinstry CS, McManus D, Morrison PJ.

Clin Dysmorphol. 2013 Apr;22(2):71-2. doi: 10.1097/MCD.0b013e32835f7465. No abstract available.

PMID:
23448906
26.

MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.

Althoff K, Beckers A, Odersky A, Mestdagh P, Köster J, Bray IM, Bryan K, Vandesompele J, Speleman F, Stallings RL, Schramm A, Eggert A, Sprüssel A, Schulte JH.

Int J Cancer. 2013 Sep 1;133(5):1064-73. doi: 10.1002/ijc.28091. Epub 2013 Mar 7.

27.

New insights into the genetics of neuroblastoma.

Sridhar S, Al-Moallem B, Kamal H, Terrile M, Stallings RL.

Mol Diagn Ther. 2013 Apr;17(2):63-9. doi: 10.1007/s40291-013-0019-6. Review.

PMID:
23329364
28.

The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL, Bray I.

Pediatr Surg Int. 2013 Feb;29(2):101-19. doi: 10.1007/s00383-012-3239-7. Epub 2012 Dec 29. Review.

29.

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH.

Nat Genet. 2012 Nov;44(11):1199-206. doi: 10.1038/ng.2436. Epub 2012 Oct 7.

PMID:
23042116
30.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

31.

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.

Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, Lynch J, Bray IM, O'Meara A, Tracey L, Davidoff AM, Stallings RL.

Br J Cancer. 2012 Sep 4;107(6):967-76. doi: 10.1038/bjc.2012.356. Epub 2012 Aug 14. Erratum in: Br J Cancer. 2012 Sep 25;107(7):1203. Tracey, L [added].

32.

Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs.

Das S, Bryan K, Buckley PG, Piskareva O, Bray IM, Foley N, Ryan J, Lynch J, Creevey L, Fay J, Prenter S, Koster J, van Sluis P, Versteeg R, Eggert A, Schulte JH, Schramm A, Mestdagh P, Vandesompele J, Speleman F, Stallings RL.

Oncogene. 2013 Jun 13;32(24):2927-36. doi: 10.1038/onc.2012.311. Epub 2012 Jul 16.

33.

Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death.

McKiernan RC, Jimenez-Mateos EM, Sano T, Bray I, Stallings RL, Simon RP, Henshall DC.

Exp Neurol. 2012 Oct;237(2):346-54. doi: 10.1016/j.expneurol.2012.06.029. Epub 2012 Jul 5.

34.

Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ.

Howley R, Kinsella P, Buckley PG, Alcock L, Jansen M, Heffernan J, Stallings RL, Brett FM, Amberger-Murphy V, Farrell MA.

Exp Cell Res. 2012 Oct 15;318(17):2245-56. doi: 10.1016/j.yexcr.2012.06.007. Epub 2012 Jun 15.

PMID:
22705586
35.

Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects.

Jimenez-Mateos EM, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, Mouri G, Sano T, O'Tuathaigh C, Waddington JL, Prenter S, Delanty N, Farrell MA, O'Brien DF, Conroy RM, Stallings RL, DeFelipe J, Henshall DC.

Nat Med. 2012 Jul;18(7):1087-94. doi: 10.1038/nm.2834.

36.

Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.

Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, Prenter S, Harvey H, Domingo-Fernández R, Bray IM, Piskareva O, Ng CY, Lode HN, Davidoff AM, Stallings RL.

PLoS One. 2012;7(5):e38129. doi: 10.1371/journal.pone.0038129. Epub 2012 May 25.

37.

Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis.

McKiernan RC, Jimenez-Mateos EM, Bray I, Engel T, Brennan GP, Sano T, Michalak Z, Moran C, Delanty N, Farrell M, O'Brien D, Meller R, Simon RP, Stallings RL, Henshall DC.

PLoS One. 2012;7(5):e35921. doi: 10.1371/journal.pone.0035921. Epub 2012 May 15.

38.

MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.

Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, Stallings RL.

Carcinogenesis. 2012 May;33(5):976-85. doi: 10.1093/carcin/bgs114. Epub 2012 Mar 1.

39.

Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene.

Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AW, Chan TA, Stallings RL.

Mol Cancer. 2012 Feb 5;11:6. doi: 10.1186/1476-4598-11-6.

40.

Differential DNA methylation patterns define status epilepticus and epileptic tolerance.

Miller-Delaney SF, Das S, Sano T, Jimenez-Mateos EM, Bryan K, Buckley PG, Stallings RL, Henshall DC.

J Neurosci. 2012 Feb 1;32(5):1577-88. doi: 10.1523/JNEUROSCI.5180-11.2012.

41.

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.

Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL.

PLoS One. 2011;6(12):e28356. doi: 10.1371/journal.pone.0028356. Epub 2011 Dec 2.

42.

miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.

De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Izycka-Swieszewska E, London WB, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, Van Roy N, Speleman F, Vandesompele J.

Clin Cancer Res. 2011 Dec 15;17(24):7684-92. doi: 10.1158/1078-0432.CCR-11-0610. Epub 2011 Oct 26.

43.

miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132.

Jimenez-Mateos EM, Bray I, Sanz-Rodriguez A, Engel T, McKiernan RC, Mouri G, Tanaka K, Sano T, Saugstad JA, Simon RP, Stallings RL, Henshall DC.

Am J Pathol. 2011 Nov;179(5):2519-32. doi: 10.1016/j.ajpath.2011.07.036. Epub 2011 Sep 23. Erratum in: Am J Pathol. 2013 Aug;183(2):641. Am J Pathol. 2013 Jul;183(1):326-8.

44.

Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.

Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Øra I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, Versteeg R, Molenaar JJ.

Oncogene. 2012 Mar 22;31(12):1571-81. doi: 10.1038/onc.2011.344. Epub 2011 Aug 22.

PMID:
21860421
45.

MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation.

Stallings RL, Foley NH, Bray IM, Das S, Buckley PG.

Semin Cancer Biol. 2011 Oct;21(4):283-90. doi: 10.1016/j.semcancer.2011.07.001. Epub 2011 Jul 13. Review.

46.

Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.

Murphy DM, Buckley PG, Das S, Watters KM, Bryan K, Stallings RL.

PLoS One. 2011;6(6):e21436. doi: 10.1371/journal.pone.0021436. Epub 2011 Jun 22.

47.

Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.

Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL.

Mol Carcinog. 2011 Jun;50(6):403-11. doi: 10.1002/mc.20722. Epub 2010 Dec 28.

PMID:
21557326
48.

MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma.

Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, Tracey L, Davidoff AM, Stallings RL.

Cancer Lett. 2011 Apr 1;303(1):56-64. doi: 10.1016/j.canlet.2011.01.016.

49.

Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker.

Buckley PG, Alcock L, Heffernan J, Woods J, Brett F, Stallings RL, Farrell MA.

J Neuropathol Exp Neurol. 2011 Mar;70(3):177-82. doi: 10.1097/NEN.0b013e31820c765b.

PMID:
21293300
50.

MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma.

Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL.

BMC Cancer. 2011 Jan 25;11:33. doi: 10.1186/1471-2407-11-33.

Supplemental Content

Loading ...
Support Center